Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Zealand Pharma A/S - Asset Resilience Ratio
Zealand Pharma A/S (ZLDPF) has an Asset Resilience Ratio of 54.33% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Zealand Pharma A/S's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Zealand Pharma A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.33 Billion | 54.33% |
| Total Liquid Assets | $9.33 Billion | 54.33% |
Asset Resilience Insights
- Very High Liquidity: Zealand Pharma A/S maintains exceptional liquid asset reserves at 54.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zealand Pharma A/S Industry Peers by Asset Resilience Ratio
Compare Zealand Pharma A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Zealand Pharma A/S (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Zealand Pharma A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 81.49% | $7.75 Billion | $9.51 Billion | +21.70pp |
| 2023-12-31 | 59.79% | $1.18 Billion | $1.98 Billion | +52.73pp |
| 2022-12-31 | 7.05% | $108.61 Million | $1.54 Billion | -7.41pp |
| 2021-12-31 | 14.46% | $299.04 Million | $2.07 Billion | -0.99pp |
| 2020-12-31 | 15.45% | $297.35 Million | $1.92 Billion | -3.27pp |
| 2019-12-31 | 18.72% | $299.45 Million | $1.60 Billion | -5.56pp |
| 2018-12-31 | 24.28% | $298.61 Million | $1.23 Billion | +14.09pp |
| 2017-12-31 | 10.19% | $75.11 Million | $737.24 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $694.63 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $634.69 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $596.76 Million | -- |
| 2013-12-31 | 7.03% | $24.38 Million | $346.91 Million | -17.34pp |
| 2012-12-31 | 24.37% | $126.94 Million | $520.98 Million | -7.45pp |
| 2011-12-31 | 31.81% | $149.36 Million | $469.48 Million | +20.05pp |
| 2010-12-31 | 11.76% | $53.00 Million | $450.55 Million | +11.11pp |
| 2009-12-31 | 0.65% | $1.03 Million | $158.68 Million | -0.41pp |
| 2008-12-31 | 1.06% | $2.40 Million | $225.24 Million | -0.63pp |
| 2007-12-31 | 1.69% | $4.46 Million | $263.37 Million | -- |